AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2013-10-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 597
- Registration Number
- NCT00680745
- Locations
- 🇺🇦
Research Site, Zaporozhye, Ukraine
Adherence in Adolescents and Children Treated on Quetiapine
- Conditions
- Psychosis
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00680888
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 99
- Registration Number
- NCT00679783
- Locations
- 🇨🇦
Research Site, Montreal, Quebec, Canada
30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease
- Conditions
- DyslipidemiaKidney Disease
- Interventions
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2012-10-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 280
- Registration Number
- NCT00680017
- Locations
- 🇺🇸
Site Reference ID/Investigator# 8095, Philadelphia, Pennsylvania, United States
🇺🇸Site Reference ID/Investigator# 22812, Dallas, Texas, United States
🇺🇸Site Reference ID/Investigator# 8136, Atlanta, Georgia, United States
Statins and Risk of Myocardial Infarction in Real Life in France
- Conditions
- Myocardial Infarction
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2010-12-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 13171
- Registration Number
- NCT00679575
- Locations
- 🇫🇷
Research Site, Villefranche de Rouergue, France
Observational Usage Study of Statins in Primary Care in France
- Conditions
- Healthy
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2010-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2100
- Registration Number
- NCT00680082
- Locations
- 🇨🇳
Research Site, Wenzhou, Zhejiang, China
Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2010-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT00679640
- Locations
- 🇫🇷
Research Site, Maisons Laffitte, Yvelines, France
Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 820
- Registration Number
- NCT00676338
- Locations
- 🇬🇧
Research Site, Swansea, United Kingdom
🇮🇱Research SIte, Tel-Hashomer, Israel
Drug-Drug Interaction Study of Esomeprazole (D961H) Capsule and Loxoprofen Tablet After Repeated Oral Administration in Japanese Males
- First Posted Date
- 2008-05-12
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00676117
- Locations
- 🇯🇵
Research Site, Osaka-city, Osaka, Japan
Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1240
- Registration Number
- NCT00673231
- Locations
- 🇬🇧
Research Site, Swansea, United Kingdom